DOCSLIB.ORG

Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma Published OnlineFirst December 12, 2013; DOI: 10.1158/0008-5472.CAN-13-1315 Cancer Molecular and Cellular Pathobiology Research Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma Eveline Barbieri1, Katleen De Preter3, Mario Capasso4, Zaowen Chen1, Danielle M. Hsu2, Gian Paolo Tonini5, Steve Lefever3, John Hicks1, Rogier Versteeg7, Andrea Pession6, Frank Speleman3, Eugene S. Kim2, and Jason M. Shohet1 Abstract Neuroblastoma arises from the embryonal neural crest secondary to a block in differentiation. Long-term patient survival correlates inversely with the extent of differentiation, and treatment with retinoic acid or other prodifferentiation agents improves survival modestly. In this study, we show the histone chaperone and epigenetic regulator CHAF1A functions in maintaining the highly dedifferentiated state of this aggressive malignancy. CHAF1A is a subunit of the chromatin modifier chromatin assembly factor 1 and it regulates H3K9 trimethylation of key target genes regulating proliferation, survival, and differentiation. Elevated CHAF1A expression strongly correlated with poor prognosis. Conversely, CHAF1A loss-of-function was sufficient to drive neuronal differentiation in vitro and in vivo. Transcriptome analysis of cells lacking CHAF1A revealed repression of oncogenic signaling pathways and a normalization of glycolytic metabolism. Our findings demonstrate that CHAF1A restricts neural crest differentiation and contributes to the pathogenesis of high-risk neuroblastoma. Cancer Res; 74(3); 1–10. Ó2013 AACR. Introduction of residual disease of stage IV neuroblastoma after multimodal Neuroblastoma arises from residual immature neural crest therapy (3). Nevertheless, rising resistance and treatment tox- cells within the peripheral sympathetic ganglia of very young icity represent relevant limiting factors, and the overall children (1). The clinical and biologic behavior of this tumor is response rate to retinoic acid in patients with neuroblastoma fi extremely heterogeneous, encompassing fatal tumor progres- is low, suggesting that only a subgroup of patients bene ts from sion, as well as spontaneous regression and differentiation into the treatment. Therefore, a better understanding of the molec- mature ganglioneuroma. Furthermore, the degree of neuronal ular mechanisms that restrict neuroblastoma differentiation tumor differentiation strongly affects patient outcome. Studies could lead to improved therapeutic approaches for this highly from transgenic mouse models of neuroblastoma with targeted aggressive malignancy. overexpression of the MYCN oncogene also demonstrate that Alterations in components of the transcriptional machinery fi blocked neural crest differentiation leads to the malignant and chromatin modi er genes are now associated with initia- transformation of neuroectodermal precursors into neuroblas- tion and differentiation of multiple cancers (4), including neu- toma (2). Efforts to define the mechanisms for this blockage in roblastoma (5). A role for epigenetics in tumorigenesis is further neuroblast differentiation have been the focus of major research supported by recent genome-wide sequencing studies revealing efforts over the past years, and have led to the incorporation of recurrent cancer-associated mutations in key epigenetic regu- fi several differentiation strategies into neuroblastoma treatment. lator genes, including histone modi ers, histone chaperones, fi Retinoic acid therapy is an important component of treatment and DNA methylation modi ers (6). In particular, methylation of histone H3 at position lysine 9 (H3K9) has been extensively studied as a major factor regulating transition between tran- Authors' Affiliations: 1Texas Children's Cancer Center and Center for Cell and Gene Therapy; 2Department of Surgery, Baylor College of Medicine, scriptionally active euchromatin and inactive heterochromatin Houston, Texas; 3Center for Medical Genetics, Ghent University, Ghent, (7). In addition, H3K9 histone methyltransferases interact with 4 Belgium; CEINGE Biotecnologie Avanzate, Department of Biochemistry and DNA methyltransferases (e.g., DNMT1/3b) to indirectly modu- Medical Biotechnology, University of Naples Federico II, Naples; 5Pediatric Research Institute, University of Padua, Padua; 6Paediatric Oncology and late gene silencing through DNA methylation (8). The histone Haematology Unit "Lalla Seragnoli," Sant'Orsola-Malpighi Hospital, Univer- modifiers EZH2 (9) and LSD1 (10) are deregulated in neuro- sity ofBologna, Bologna,Italy; and 7DepartmentofOncogenomics,Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands blastoma with high expression conferring worse prognosis. In addition, repression of the tumor suppressor and chromatin Note: Supplementary data for this article are available at Cancer Research fi Online (http://cancerres.aacrjournals.org/). modi er CHD5 through loss of heterozygosity and DNA meth- ylation negatively correlates with long-term survival (11). Corresponding Author: Jason M. Shohet, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Feigin CHAF1A (CAF p150) is a primary component of the chro- Building, Room 750.01, 1102 Bates Street, Houston, TX 77030. Phone: matin assembly factor 1 (CAF-1), composed of p150, p60, and 832-824-4735; Fax: 832-825-1604; E-mail: [email protected] p48 subunits, which promotes rapid assembly of nucleosomes doi: 10.1158/0008-5472.CAN-13-1315 on newly replicated DNA (12). The importance of CHAF1A in Ó2013 American Association for Cancer Research. cancer pathogenesis is supported by the finding that its www.aacrjournals.org OF1 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst December 12, 2013; DOI: 10.1158/0008-5472.CAN-13-1315 Barbieri et al. overexpression has been linked to tumor progression (13), inter-run calibration, and error propagation) were performed cancer susceptibility (14), and more recently, epigenetic silenc- in qBasePlus version 1.1 (19, 20). ing (15). In addition, CHAF1A participates in a complex with MBD1 and SETDB1 during initiation of a gene-silencing pro- Short hairpin RNA constructs and antibodies gram by promoting H3K9 trimethylation, heterochromatin For p53 short hairpin RNA (shRNA), second-generation formation, and DNA methylation (16). lentiviruses expressing shp53 and shLuc control were used as We show here that CHAF1A restricts neuroblastoma differ- described (21). To knock down CHAF1A expression, a TRIPZ entiation using both in vitro and in vivo orthotopic models. lentiviral inducible shRNAmir with Tet-inducible promoter Elevated expression of CHAF1A indeed strongly correlates was used (Open Biosystems). The tetracycline response ele- clinically with an undifferentiated neuroblastoma phenotype ment (TRE) promoter also drives the expression of a TurboRFP and poor overall survival. We also demonstrate that CHAF1A reporter. To repress CHAF1A expression, doxycycline was promotes oncogenic signaling pathways (including RAS, AKT, added at a final concentration of 1 mg/mL. Control lines using BMI1, and WNT) as well as alters glycolytic metabolism path- scrambled shRNAmir were also generated. A GIPZ lentiviral ways. Together, these data support a novel function for the stable shRNA (Open Biosystems) was instead used to trans- histone modifier CHAF1A restricting neural crest differentia- duce neuroblastoma lines for in vivo studies. Briefly, 293T cells tion and promoting neuroblastoma tumorigenesis. were transfected with pLSLPw, TRIPZ, and GIPZ constructs along with packaging plasmids, pVSVG, and pLV-CMV-delta Patients and Methods 8.2 by using lipofectamine. Virus-containing supernatants Clinical patient cohort groups were collected at 48 and 72 hours and neuroblastoma cells Discovery set 1. Versteeg (n ¼ 88). This dataset of 88 unique were transduced in the presence of 8 mg/mL polybrene tumors was profiled on the Affymetrix HGU133 plus2.0 platform (Sigma). CHAF1A rabbit monoclonal antibodies (Epitomics; and normalized using the MASS5.0 algorithm. Expression data #5464-1; 1:500 dilution) and p53 mouse monoclonal antibodies were freely downloaded from the R2 website (http://r2.amc.nl). (Sigma; #P6874; 1:1,000 dilution) were used for Western blot- Validation set 2. Vermeulen (n ¼ 348). This cohort includ- ting. Anti-H3K9me3 antibodies (22-442; Millipore) were used at ed 348 patients with neuroblastoma taken from the Interna- a dilution 1:1,000 after acid extraction of the histones. tional Society of Pediatric Oncology, European Neuroblastoma Group (SIOPEN) and from the Gesellschaft fuer Paediatrische Xenograft model Onkologie und Haematologie (GPOH). Patients were only Orthotopic xenografts of human neuroblastoma were gen- included if primary untreated neuroblastoma tumor RNA (at erated as described previously (23) by injection under the renal 6 least 60% tumor cells and confirmed histologic diagnosis of capsule of an inoculum of 10 tumor cells in 0.1 mL of PBS. neuroblastoma) was available and of sufficient quality (17). Tumors were evaluated at necropsy 5 weeks after inoculation. Almost all patients were treated according to the SIOPEN protocols. The median follow-up was 63 months and greater Oligonucleotide microarray data analysis than 24 months for most patients (91%). In this cohort, 32% of Total RNA was isolated using the RNAeasy Kit (Quiagen) the patients had stage I disease, 18% stage II, 18% stage III, 23% from IMR32 cells transduced with inducible
Load more

Recommended publications
  • Regulation of Oxidized Base Damage Repair by Chromatin Assembly Factor 1 Subunit a Chunying Yang1,*,†, Shiladitya Sengupta1,2,*,†, Pavana M
    Published online 27 October 2016 Nucleic Acids Research, 2017, Vol. 45, No. 2 739–748 doi: 10.1093/nar/gkw1024 Regulation of oxidized base damage repair by chromatin assembly factor 1 subunit A Chunying Yang1,*,†, Shiladitya Sengupta1,2,*,†, Pavana M. Hegde1,JoyMitra1, Shuai Jiang3, Brooke Holey3, Altaf H. Sarker3, Miaw-Sheue Tsai3, Muralidhar L. Hegde1,2,4 and Sankar Mitra1,2,* 1Department of Radiation Oncology, Houston Methodist Research Institute, Houston, TX 77030, USA, 2Weill Cornell Medical College, Cornell University, New York, NY 10065, USA, 3Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA and 4Houston Methodist Neurological Institute, Houston, TX 77030, USA Received March 23, 2016; Revised October 13, 2016; Editorial Decision October 17, 2016; Accepted October 19, 2016 ABSTRACT INTRODUCTION Reactive oxygen species (ROS), generated both en- ROS, continuously generated in mammalian cells both en- dogenously and in response to exogenous stress, in- dogenously and by environmental genotoxicants, induce duce point mutations by mis-replication of oxidized various genomic lesions, including oxidized bases, abasic bases and other lesions in the genome. Repair of (AP) sites and single-strand breaks (SSBs). If unrepaired or these lesions via base excision repair (BER) pathway mis-repaired, DNA lesions would cause mutations which may lead to cytotoxicity and cell death and also carcino- maintains genomic fidelity. Regulation of the BER genic transformation (1). The base excision repair (BER) pathway for mutagenic oxidized bases, initiated by pathway, responsible for repair of oxidized base lesions NEIL1 and other DNA glycosylases at the chromatin which contribute to drug/radiation sensitivity is highly con- level remains unexplored.
    [Show full text]
  • Supplementary Data
    SUPPLEMENTARY DATA A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma Santiago Demajo et al. 1 SUPPLEMENTARY DATA INDEX Supplementary Methods p. 3 Supplementary References p. 8 Supplementary Tables (S1 to S5) p. 9 Supplementary Figures (S1 to S15) p. 17 2 SUPPLEMENTARY METHODS Western blot, immunoprecipitation, and qRT-PCR Western blot (WB) analysis was performed as previously described (1), using cyclin D1 (Santa Cruz Biotechnology, sc-753, RRID:AB_2070433) and tubulin (Sigma-Aldrich, T5168, RRID:AB_477579) antibodies. Co-immunoprecipitation assays were performed as described before (2), using cyclin D1 antibody (Santa Cruz Biotechnology, sc-8396, RRID:AB_627344) or control IgG (Santa Cruz Biotechnology, sc-2025, RRID:AB_737182) followed by protein G- magnetic beads (Invitrogen) incubation and elution with Glycine 100mM pH=2.5. Co-IP experiments were performed within five weeks after cell thawing. Cyclin D1 (Santa Cruz Biotechnology, sc-753), E2F4 (Bethyl, A302-134A, RRID:AB_1720353), FOXM1 (Santa Cruz Biotechnology, sc-502, RRID:AB_631523), and CBP (Santa Cruz Biotechnology, sc-7300, RRID:AB_626817) antibodies were used for WB detection. In figure 1A and supplementary figure S2A, the same blot was probed with cyclin D1 and tubulin antibodies by cutting the membrane. In figure 2H, cyclin D1 and CBP blots correspond to the same membrane while E2F4 and FOXM1 blots correspond to an independent membrane. Image acquisition was performed with ImageQuant LAS 4000 mini (GE Healthcare). Image processing and quantification were performed with Multi Gauge software (Fujifilm). For qRT-PCR analysis, cDNA was generated from 1 µg RNA with qScript cDNA Synthesis kit (Quantabio). qRT–PCR reaction was performed using SYBR green (Roche).
    [Show full text]
  • Differential Expression Profile Analysis of DNA Damage Repair Genes in CD133+/CD133‑ Colorectal Cancer Cells
    ONCOLOGY LETTERS 14: 2359-2368, 2017 Differential expression profile analysis of DNA damage repair genes in CD133+/CD133‑ colorectal cancer cells YUHONG LU1*, XIN ZHOU2*, QINGLIANG ZENG2, DAISHUN LIU3 and CHANGWU YUE3 1College of Basic Medicine, Zunyi Medical University, Zunyi; 2Deparment of Gastroenterological Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi;3 Zunyi Key Laboratory of Genetic Diagnosis and Targeted Drug Therapy, The First People's Hospital of Zunyi, Zunyi, Guizhou 563003, P.R. China Received July 20, 2015; Accepted January 6, 2017 DOI: 10.3892/ol.2017.6415 Abstract. The present study examined differential expression cells. By contrast, 6 genes were downregulated and none levels of DNA damage repair genes in COLO 205 colorectal were upregulated in the CD133+ cells compared with the cancer cells, with the aim of identifying novel biomarkers for COLO 205 cells. These findings suggest that CD133+ cells the molecular diagnosis and treatment of colorectal cancer. may possess the same DNA repair capacity as COLO 205 COLO 205-derived cell spheres were cultured in serum-free cells. Heterogeneity in the expression profile of DNA damage medium supplemented with cell factors, and CD133+/CD133- repair genes was observed in COLO 205 cells, and COLO cells were subsequently sorted using an indirect CD133 205-derived CD133- cells and CD133+ cells may therefore microbead kit. In vitro differentiation and tumorigenicity assays provide a reference for molecular diagnosis, therapeutic target in BABA/c nude mice were performed to determine whether selection and determination of the treatment and prognosis for the CD133+ cells also possessed stem cell characteristics, in colorectal cancer.
    [Show full text]
  • Table 1. a Selection of Eukaryotic Genes with a Role in the Maintenance of Genome Integrity
    Table 1. A selection of eukaryotic genes with a role in the maintenance of genome integrity Process S. cerevisiae Mammals Function Human Disease Cancer* GCR* HR* Replication CAC1, 2, 3 CHAF1A,B,p48 Chromatin assembly high high 1, 2 1, 2 ASF1 ASF1A Chromatin assembly high high 3 TOP1 TOP1 Topoisomerase I high 3 TOP2 TOP2 Topoisomerase II high Replicative helicase 4, 5 MCM4 MCM4 yes high subunit Origin Replication 6 ORC3/5 ORC3/6L high complex 7 CDC6 CDC6 Replication Initiation high 7, 8 CDC9 LIG1 Ligase I high POL1/ 7-10 POLA1/PRIM1,2 Polymerase α/Primase high high PRI1,2 Polymerase ε subunit, 6, 11 DPB11 TOBP11 high checkpoint mediator POL3/CDC2 POLD1 Polymerase δ high 7, 8 POL30 PCNA PCNA normal high 12, 13 RAD27 FEN1 Flap endonuclease high high 14-16 Replication Factor A, 14, RFA1,2,3 RPA70,32,14 yes high high 17-19 checkpoint signalling PIF1 PIF1 RNA-DNA helicase high 20, 21 RRM3 unknown DNA Helicase normal high 22-26 Clamp loader, 11, RFC1-5 RFC1-5 high high 20, 27 checkpoint Checkpoint PDS1 PDS1 Mitotic arrest high 11, 28 Damage checkpoint 11, 29 RAD9 unknown high high mediator 11, MEC1 ATR Transducer kinase Seckel syndrome high high 28, 30, 31 Ataxia TEL1 ATM Transducer kinase Telangiectasia yes high high 11, 28 (AT) CHK1 CHEK1 Effector kinase Rare tumours yes high 11 Li-Fraumeni RAD53 CHEK2 Effector kinase syndrome yes high 11 variant DUN1 unknown Effector kinase high high 11, 32 DDC1- RAD9-RAD1- 11 RAD17- PCNA-like complex high HUS1 MEC3 RFC-like, S-phase 11, 33 RAD24 RAD17 high high checkponit 34 CTF18 CHTF18 RFC-like, Cohesion
    [Show full text]
  • The Genetic Program of Pancreatic Beta-Cell Replication in Vivo
    Page 1 of 65 Diabetes The genetic program of pancreatic beta-cell replication in vivo Agnes Klochendler1, Inbal Caspi2, Noa Corem1, Maya Moran3, Oriel Friedlich1, Sharona Elgavish4, Yuval Nevo4, Aharon Helman1, Benjamin Glaser5, Amir Eden3, Shalev Itzkovitz2, Yuval Dor1,* 1Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 2Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. 3Department of Cell and Developmental Biology, The Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel 4Info-CORE, Bioinformatics Unit of the I-CORE Computation Center, The Hebrew University and Hadassah, The Institute for Medical Research Israel- Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 5Endocrinology and Metabolism Service, Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel *Correspondence: [email protected] Running title: The genetic program of pancreatic β-cell replication 1 Diabetes Publish Ahead of Print, published online March 18, 2016 Diabetes Page 2 of 65 Abstract The molecular program underlying infrequent replication of pancreatic beta- cells remains largely inaccessible. Using transgenic mice expressing GFP in cycling cells we sorted live, replicating beta-cells and determined their transcriptome. Replicating beta-cells upregulate hundreds of proliferation- related genes, along with many novel putative cell cycle components. Strikingly, genes involved in beta-cell functions, namely glucose sensing and insulin secretion were repressed. Further studies using single molecule RNA in situ hybridization revealed that in fact, replicating beta-cells double the amount of RNA for most genes, but this upregulation excludes genes involved in beta-cell function.
    [Show full text]
  • CHAF1A–PCNA Interaction Promotes Cervical Cancer Progression Via the PI3K/AKT/Foxo1 Signaling Pathway
    CHAF1A–PCNA interaction promotes cervical cancer progression via the PI3K/AKT/FoxO1 signaling pathway Li Wen Department of Gynecology, the First Aliated Hospital of Chongqing Medical University Yuli Luo Obstetrics and Gynecology, People's Hospital of Hechuan District, Chongqing Municipality Zhaoning Duan Department of Gynecology, the First Aliated Hospital of Chongqing Medical University Xiaoge Li Department of Gynecology, the First Aliated Hospital of Chongqing Medical University Ying Jia ( [email protected] ) Department of Gynecology, the First Aliated Hospital of Chongqing Medical University https://orcid.org/0000-0002-1602-3122 Primary research Keywords: Cervical cancerCHAF1APCNAInteraction Posted Date: April 12th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-390228/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/18 Abstract Background An increasing number of studies demonstrate that histone chaperones play critical roles in tumorigenesis and development. In previous research, we conrmed that CHAF1A was highly expressed in cervical cancer (CC) and was correlated with poor prognosis. However, the biological function and specic mechanism of CHAF1A in the development of CC have not been reported. Methods CHAF1A knockdown in SiHa and HeLa.cells by lentivirus vector is veried by RT-PCR and Western blot analysis.CCK-8, ow cytometry assays, colony formation, cell migration assay and real-time cell analysis assay were performed to determine the cellular function of CHAF1A in CC.Tumor xenograft assay was conducted on nude mice to assess the effect of CHAF1A in vivo. Cell immunouorescence and co- immunoprecipitation were applied to examine the interaction between CHAF1A and PCNA.
    [Show full text]
  • The HUSH Complex Cooperates with TRIM28 to Repress Young Retrotransposons and New Genes
    Downloaded from genome.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Research The HUSH complex cooperates with TRIM28 to repress young retrotransposons and new genes Luisa Robbez-Masson,1 Christopher H.C. Tie,1 Lucia Conde,2 Hale Tunbak,1 Connor Husovsky,1 Iva A. Tchasovnikarova,3 Richard T. Timms,3 Javier Herrero,2 Paul J. Lehner,3 and Helen M. Rowe1 1Infection and Immunity, University College London, London WC1E 6BT, United Kingdom; 2Bill Lyons Informatics Centre, UCL Cancer Institute, University College London, London WC1E 6DD, United Kingdom; 3Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom Retrotransposons encompass half of the human genome and contribute to the formation of heterochromatin, which pro- vides nuclear structure and regulates gene expression. Here, we asked if the human silencing hub (HUSH) complex is nec- essary to silence retrotransposons and whether it collaborates with TRIM28 and the chromatin remodeler ATRX at specific genomic loci. We show that the HUSH complex contributes to de novo repression and DNA methylation of an SVA retro- transposon reporter. By using naıvë versus primed mouse pluripotent stem cells, we reveal a critical role for the HUSH com- plex in naıvë cells, implicating it in programming epigenetic marks in development. Although the HUSH component FAM208A binds to endogenous retroviruses (ERVs) and long interspersed element-1s (LINE-1s or L1s), it is mainly required to repress evolutionarily young L1s (mouse-specific lineages <5 million years old). TRIM28, in contrast, is necessary to repress both ERVs and young L1s. Genes co-repressed by TRIM28 and FAM208A are evolutionarily young, or exhibit tissue-specific expression, are enriched in young L1s, and display evidence for regulation through LTR promoters.
    [Show full text]
  • Cell Cycle Arrest Through Indirect Transcriptional Repression by P53: I Have a DREAM
    Cell Death and Differentiation (2018) 25, 114–132 Official journal of the Cell Death Differentiation Association OPEN www.nature.com/cdd Review Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM Kurt Engeland1 Activation of the p53 tumor suppressor can lead to cell cycle arrest. The key mechanism of p53-mediated arrest is transcriptional downregulation of many cell cycle genes. In recent years it has become evident that p53-dependent repression is controlled by the p53–p21–DREAM–E2F/CHR pathway (p53–DREAM pathway). DREAM is a transcriptional repressor that binds to E2F or CHR promoter sites. Gene regulation and deregulation by DREAM shares many mechanistic characteristics with the retinoblastoma pRB tumor suppressor that acts through E2F elements. However, because of its binding to E2F and CHR elements, DREAM regulates a larger set of target genes leading to regulatory functions distinct from pRB/E2F. The p53–DREAM pathway controls more than 250 mostly cell cycle-associated genes. The functional spectrum of these pathway targets spans from the G1 phase to the end of mitosis. Consequently, through downregulating the expression of gene products which are essential for progression through the cell cycle, the p53–DREAM pathway participates in the control of all checkpoints from DNA synthesis to cytokinesis including G1/S, G2/M and spindle assembly checkpoints. Therefore, defects in the p53–DREAM pathway contribute to a general loss of checkpoint control. Furthermore, deregulation of DREAM target genes promotes chromosomal instability and aneuploidy of cancer cells. Also, DREAM regulation is abrogated by the human papilloma virus HPV E7 protein linking the p53–DREAM pathway to carcinogenesis by HPV.Another feature of the pathway is that it downregulates many genes involved in DNA repair and telomere maintenance as well as Fanconi anemia.
    [Show full text]
  • SUPPORTING INFORMATION for Regulation of Gene Expression By
    SUPPORTING INFORMATION for Regulation of gene expression by the BLM helicase correlates with the presence of G4 motifs Giang Huong Nguyen1,2, Weiliang Tang3, Ana I. Robles1, Richard P. Beyer4, Lucas T. Gray5, Judith A. Welsh1, Aaron J. Schetter1, Kensuke Kumamoto1,6, Xin Wei Wang1, Ian D. Hickson2,7, Nancy Maizels5, 3,8 1 Raymond J. Monnat, Jr. and Curtis C. Harris 1Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A; 2Department of Medical Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, U.K.; 3Department of Pathology, University of Washington, Seattle, WA U.S.A.; 4 Center for Ecogenetics and Environmental Health, University of Washington, Seattle, WA U.S.A.; 5Department of Immunology and Department of Biochemistry, University of Washington, Seattle, WA U.S.A.; 6Department of Organ Regulatory Surgery, Fukushima Medical University, Fukushima, Japan; 7Cellular and Molecular Medicine, Nordea Center for Healthy Aging, University of Copenhagen, Denmark; 8Department of Genome Sciences, University of WA, Seattle, WA U.S.A. SI Index: Supporting Information for this manuscript includes the following 19 items. A more detailed Materials and Methods section is followed by 18 Tables and Figures in order of their appearance in the manuscript text: 1) SI Materials and Methods 2) Figure S1. Study design and experimental workflow. 3) Figure S2. Immunoblot verification of BLM depletion from human fibroblasts. 4) Figure S3. PCA of mRNA and miRNA expression in BLM-depleted human fibroblasts. 5) Figure S4. qPCR confirmation of mRNA array data. 6) Table S1. BS patient and control detail.
    [Show full text]
  • CHAF1A (D77D5) XP Rabbit Mab A
    Revision 1 C 0 2 ® - t CHAF1A (D77D5) XP Rabbit mAb a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 0 8 Web: [email protected] 4 www.cellsignal.com 5 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source/Isotype: UniProt ID: Entrez-Gene Id: WB, IP, IF-IC H Mk Endogenous 145 Rabbit IgG Q13111 10036 Product Usage Information 7. Polo, S.E. et al. (2004) Cancer Res 64, 2371-81. Application Dilution Western Blotting 1:1000 Immunoprecipitation 1:100 Immunofluorescence (Immunocytochemistry) 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity CHAF1A (D77D5) XP® Rabbit mAb detects endogenous levels of total CHAF1A protein. Species Reactivity: Human, Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro303 of human CHAF1A protein. Background Chromatin assembly factor 1 (CAF-1) is a histone H3/H4 chaperone complex that functions in de novo assembly of nucleosomes during DNA replication and nucleotide excision repair (1). Nucleosome assembly is a two-step process, involving initial deposition of a histone H3/H4 tetramer onto DNA, followed by the deposition of a pair of histone H2A/H2B dimers (1). CAF-1 interacts with PCNA and localizes to DNA replication and DNA repair foci, where it functions to assemble newly synthesized histone H3/H4 tetramers onto replicating DNA (2-6).
    [Show full text]
  • Host Protein Interactions
    scientificscientificreport report Structure homology and interaction redundancy for discovering virus–host protein interactions Benoıˆt de Chassey 1,Laure`ne Meyniel-Schicklin 2,3, Anne Aublin-Gex 2,3, Vincent Navratil 2,3,w, Thibaut Chantier 2,3, Patrice Andre´1,2,3 &VincentLotteau2,3+ 1Hospices Civils de Lyon, Hoˆpital de la Croix-Rousse, Laboratoire de virologie, Lyon , 2Inserm, U1111, Lyon , and 3Universite´ de Lyon, Lyon, France Virus–host interactomes are instrumental to understand global purification coupled to mass spectrometry, led to the publication perturbations of cellular functions induced by infection and of the first virus–host interactomes [3–4]. Although incorporation discover new therapies. The construction of such interactomes is, of data from different methods or variation of the same method [5] however, technically challenging and time consuming. Here we has improved the quality of the data sets, diversification of describe an original method for the prediction of high-confidence methods is still clearly needed to generate high-quality interactions between viral and human proteins through comprehensive virus–host interactomes. In addition, regarding a combination of structure and high-quality interactome data. the size of host genome and the huge diversity of viruses, millions Validation was performed for the NS1 protein of the influenza of binary interactions remain to be tested. Therefore, accurate and virus, which led to the identification of new host factors that rapid methods for the identification of cellular interactors control viral replication. controlling viral replication is a major issue and a crucial step Keywords: interactome; prediction; protein interaction; towards the selection of original therapeutic targets and drug structure; virus development.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology published online 1 July 2016 from submission to initial decision 4 weeks from acceptance to publication http://www.jimmunol.org/content/early/2016/07/01/jimmun ol.1600589 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. Published July 1, 2016, doi:10.4049/jimmunol.1600589 The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh,* Sonia M. Leach,† Brandon L. Moore,* Tullia C. Bruno,* Jonathan D. Buhrman,* and Jill E.
    [Show full text]